Literature DB >> 17222316

Long-term outcome of Crohn's disease following corticosteroid-induced remission.

Claudio Papi1, Virginia Festa, Gioacchino Leandro, Alessandra Moretti, Monica Tanga, Maurizio Koch, Lucio Capurso.   

Abstract

INTRODUCTION: Corticosteroids are the gold standard in the treatment of moderate to severe Crohn's disease but are often associated with severe and potentially dangerous side effects. Despite an initial clinical response many patients become steroid dependent or require further steroid courses in the long term. The aim of the present study was to assess the probability of the need for further steroid treatment in Crohn's disease patients following steroid-induced remission and to establish if clinical variables can predict further steroid needs. PATIENTS AND All
METHODS: patients at their first steroid course and with corticosteroid-induced remission, defined as a Crohn's Disease Activity Index (CDAI) <150, 4 wk after steroid weaning, were studied and observed at follow-up for 12 months. The main outcome was clinical relapse requiring further steroid treatment. Statistical analysis was performed using the Kaplan-Meier method and multivariable Cox proportional hazard regression model taking into consideration gender, age at diagnosis, disease location and behavior, smoking habits, CDAI score before steroid treatment, and C reactive protein values at steroid weaning, as covariates.
RESULTS: A total of 77 patients with steroid-induced remission were included. One-year follow-up was available in 75 of the 77 patients (97.4%). During follow-up 49 of 75 patients (65.3%) maintained remission or presented mild relapse not requiring steroids while 26 of 75 patients (34.6%) had moderate to severe relapse requiring further steroid treatment. The cumulative probability of a course free from steroids was 93.3%, 82.6%, 78.6%, and 66.6% at 3, 6, 9, and 12 months, respectively. At multivariate analysis, increased C reactive protein at steroid weaning and penetrating complications were independent risk factors for further steroid requirement (OR 5.57, 95% CI 1.20-25.91, P= 0.001 and OR 4.20, 95% CI 1.76-10.04, P= 0.005, respectively).
CONCLUSION: Despite an initial clinical response and successful steroid tapering, 35% of patients required further steroid treatment within 1 yr. An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222316     DOI: 10.1111/j.1572-0241.2007.01055.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

Review 2.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

Review 3.  Steroid use in Crohn's disease.

Authors:  Stephan R Vavricka; Alain M Schoepfer; Michael Scharl; Gerhard Rogler
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

4.  Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease.

Authors:  Jae Jun Park; Jae Hee Cheon; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2011-11-06       Impact factor: 3.199

Review 5.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.

Authors:  James D Lewis
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

Review 6.  Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach.

Authors:  Maria Josefina Etchevers; Ingrid Ordás; Elena Ricart
Journal:  Drugs       Date:  2010       Impact factor: 9.546

7.  A randomized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patients.

Authors:  Amrollah Sharifi; Mohammad Javad Hosseinzadeh-Attar; Homayoon Vahedi; Saharnaz Nedjat
Journal:  Saudi J Gastroenterol       Date:  2016 Jul-Aug       Impact factor: 2.485

8.  Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn's disease.

Authors:  Duk Hwan Kim; Jae Hee Cheon; Jae Jun Park; Jin Young Yoon; Chang Mo Moon; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2013-01-11       Impact factor: 4.519

9.  Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.

Authors:  Joana Torres; Flavio Caprioli; Konstantinos H Katsanos; Triana Lobatón; Dejan Micic; Marco Zerôncio; Gert Van Assche; James C Lee; James O Lindsay; David T Rubin; Remo Panaccione; Jean-Frédéric Colombel
Journal:  J Crohns Colitis       Date:  2016-06-09       Impact factor: 9.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.